Search hospitals > Tennessee > Chattanooga
Erlanger Medical Center
Claim this profileChattanooga, Tennessee 37403
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Stroke
Conducts research for Atrial Fibrillation
Conducts research for Skin Cancer
68 reported clinical trials
4 medical researchers
Summary
Erlanger Medical Center is a medical facility located in Chattanooga, Tennessee. This center is recognized for care of Breast Cancer, Cancer, Stroke, Atrial Fibrillation, Skin Cancer and other specialties. Erlanger Medical Center is involved with conducting 68 clinical trials across 137 conditions. There are 4 research doctors associated with this hospital, such as Megan Coylewright, MD,MPH,FACC, Matthew T. Oliver, Patrick Stevens, MD, and Harish Manyam, MD.Area of expertise
1Breast Cancer
Global LeaderER positive
PR positive
HER2 negative
2Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Megan Coylewright, MD,MPH,FACCErlanger Medical Center6 years of reported clinical research
Studies Stroke
Studies Bleeding
6 reported clinical trials
11 drugs studied
Matthew T. OliverWomen and Infants Hospital1 year of reported clinical research
Studies Cancer
Studies Ovarian Cancer
5 reported clinical trials
13 drugs studied
Patrick Stevens, MDErlanger Medical Center2 years of reported clinical research
Studies Aortic Valve Stenosis
Studies Tricuspid Regurgitation
2 reported clinical trials
4 drugs studied
Harish Manyam, MDErlanger Health System6 years of reported clinical research
Studies Cardiac Arrhythmias
Studies Ventricular Arrhythmia
2 reported clinical trials
2 drugs studied
Clinical Trials running at Erlanger Medical Center
Stroke
Patent Foramen Ovale
Ischemic Stroke
Transient Ischemic Attack
Aortic Valve Stenosis
Bleeding
Atrial Fibrillation
Ischemia
Stroke Prevention
AMPLATZER PFO Occluder
for Patent Foramen Ovale
The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder in the post Approval Setting.
Recruiting1 award N/A1 criteria
Left Atrial Appendage Occlusion vs. NOAC
for Atrial Fibrillation
The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Control Group"). The choice of NOAC in the Control Group will be left to study physician discretion.
Recruiting1 award N/A8 criteria
Asundexian
for Stroke Prevention
This trial is testing asundexian, a new medicine that prevents blood clots, in people who had a non-heart-related stroke or high-risk mini-stroke. The goal is to see if it works better at reducing future strokes without increasing bleeding risks. Asundexian is developed by Bayer AG and might prevent thrombosis without increasing bleeding.
Recruiting1 award Phase 3
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Erlanger Medical Center?
Erlanger Medical Center is a medical facility located in Chattanooga, Tennessee. This center is recognized for care of Breast Cancer, Cancer, Stroke, Atrial Fibrillation, Skin Cancer and other specialties. Erlanger Medical Center is involved with conducting 68 clinical trials across 137 conditions. There are 4 research doctors associated with this hospital, such as Megan Coylewright, MD,MPH,FACC, Matthew T. Oliver, Patrick Stevens, MD, and Harish Manyam, MD.